However, the measurement of sIL-2R is simple compared to the complex story behind this biomarker that has become so central to the study of immune-mediated disease. Why measure soluble interleukin-2 ...
New York, USA, July 10, 2025 (GLOBE NEWSWIRE) -- Interleukin-2 Inhibitors Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight ...
Interleukin-2 (IL-2) was discovered as a cytokine that supports the proliferation and differentiation of effector T cells. IL-2 initially entered clinical development based on this activity, in ...
Interleukins (ILs), a group of cytokines, are produced by leukocytes and non-immune cells like endothelial, fibroblasts, smooth muscle, epithelial and bone marrow cells. 1 ILs mainly act as ...
Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of Texas ...
However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease ...
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according ...
Interleukin-2, a cytokine that helps the immune system fight disease, is an FDA-approved treatment, but it has been associated with selectivity, toxicity and dosing issues. Those shortcomings have ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored therapy to treat cancer, today announced the first patient dosed in a visceral tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback